Stockreport

Upstream Bio: Hold Rating As Verekitug Faces Competition Among Latest Asthma Data [Seeking Alpha]

Upstream Bio, Inc.  (UPB) 
PDF Verekitug achieved a 56% AAER reduction at 100 mg Q12W and 39% at 400 mg Q24W, offering competitive dosing versus Tezspire. Competitive threats loom as multiple compa [Read more]